GRACEcast Radiation Oncology Video
Activity Overview
Episode publication activity over the past year
Episodes
Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
31 Jul 2014
Contributed by Lukas
Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.
Management of Rare Kidney Tumors
29 Jul 2014
Contributed by Lukas
What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient shoul...
Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?
27 Jul 2014
Contributed by Lukas
The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.
NanoString Treatment for Kidney Cancer
24 Jul 2014
Contributed by Lukas
NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be m...
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?
22 Jul 2014
Contributed by Lukas
Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical i...
How is the Heng Criteria Applied to Kidney Cancer Patients?
20 Jul 2014
Contributed by Lukas
Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
17 Jul 2014
Contributed by Lukas
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had m...
What is PD1 and PDL1 in Kidney Cancer?
15 Jul 2014
Contributed by Lukas
Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney canc...
Zykadia for ALK Positive Lung Cancer: New Drug, New Hope
13 Jul 2014
Contributed by Lukas
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side e...
No Clear Answer for Non-Clear Cell Kidney Cancer
10 Jul 2014
Contributed by Lukas
Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperate...
What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer
08 Jul 2014
Contributed by Lukas
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetM...
Treating Newly Diagnosed Kidney Cancer
06 Jul 2014
Contributed by Lukas
Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.
MET-Amplified Lung Cancer: A New Target for XALKORI?
03 Jul 2014
Contributed by Lukas
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.
The Hottest Thing in Late Stage Kidney Cancer
01 Jul 2014
Contributed by Lukas
Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.
CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer
29 Jun 2014
Contributed by Lukas
Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side eff...
The Promise of PD1 Inhibitors in Kidney Cancer
26 Jun 2014
Contributed by Lukas
Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and doctors reasons to be hopeful.
FGFR and Its Role in Treating Squamous Cell Lung Cancer
25 Jun 2014
Contributed by Lukas
Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what the...
AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer
24 Jun 2014
Contributed by Lukas
EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.
What Are Heat Shock Protein (HSP) 90 Inhibitors and How May They Help Fight Lung Cancer?
23 Jun 2014
Contributed by Lukas
"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes...
What Is Non-Clear Cell Kidney Cancer?
22 Jun 2014
Contributed by Lukas
Among kidney cancer patients, the sub-type "non-clear cell" is the least common. As a result, not much research has been conducted on it.
The Promise of Immunotherapy in Lung Cancer
18 Jun 2014
Contributed by Lukas
Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and e...
Does Gilotrif Help EGFR Positive Lung Cancer Patients?
18 Jun 2014
Contributed by Lukas
An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.
Is Progression-Free Survival Meaningful?
17 Jun 2014
Contributed by Lukas
Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate ...
DDR2 Mutations in Squamous Cell Lung Cancer
16 Jun 2014
Contributed by Lukas
A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.
Does Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients?
12 Jun 2014
Contributed by Lukas
Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab...
What is FGFR, and Could It Be a Valuable Target for Patients with Lung Cancer?
11 Jun 2014
Contributed by Lukas
Dr. Joel Neal of Stanford University Medical Center talks about FGFR - fibroblast growth factor receptor - and how it can impact non-small cell lung c...
How Do We Make EGFR Inhibitors Work Better for Patients
09 Jun 2014
Contributed by Lukas
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
TH 302: New Drug May Make Tumors Less Resistant to Treatment
04 Jun 2014
Contributed by Lukas
Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.
Should We Do Broad Sequencing of All Lung Tumors?
01 Jun 2014
Contributed by Lukas
How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumor...
How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?
29 May 2014
Contributed by Lukas
Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great pr...
Why Are Non-Mutated EGFR Genes Called "Wild Type?"
27 May 2014
Contributed by Lukas
When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University Medical Center explains why non-mutated genes a...
Teaching the Immune System to Attack Lung Cancer Tumors
25 May 2014
Contributed by Lukas
Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer...
Advice for Lung Cancer Patients: Know Thy Cancer
22 May 2014
Contributed by Lukas
What should lung cancer patients know about their disease? Dr. Jonathan Riess argues that patients should understand what type of lung cancer they hav...
Is It Necessary for Early Stage Lung Cancer Patients to Get Molecular Testing for Their Tumors?
21 May 2014
Contributed by Lukas
If you were diagnosed with early stage lung cancer, should you receive molecular testing on your tumor in order to get targeted therapy? Dr. Joel Neal...
Treating EGFR Patients After Tarceva Stops Working
19 May 2014
Contributed by Lukas
Tarceva (erlotinib) has greatly helped EGFR positive lung cancer patients, but eventually it stops working. Dr. Jonathan Goldman of UCLA Jonsson Compr...
Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive Non-small Cell Lung Cancer?
15 May 2014
Contributed by Lukas
Dr. Joel Neal of Stanford University Medical Center discusses the SELECT clinical trial which studied early stage non-small cell lung cancer patients ...
An Update on ECOG 1505: Will Avastin (Bevacizumab) Become Standard Treatment for Early Stage Lung Cancer Patients?
14 May 2014
Contributed by Lukas
Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patie...
Targeted Treatment for Lung Cancer After Progression
13 May 2014
Contributed by Lukas
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute discusses whether or not patients on targeted therapies, such as EGFR inhibitors, should stay on t...
Can Vaccines Fight Lung Cancer?
12 May 2014
Contributed by Lukas
Dr. Charles Rudin of Memorial Sloan Kettering on the possibility of using vaccines to fight lung cancer. February 2014.
CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients
11 May 2014
Contributed by Lukas
Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 201...
Why Do We Call Them "Small Cell Lung Cancer" and "Non-Small Cell Lung Cancer"?
08 May 2014
Contributed by Lukas
Dr. Cathy Pietanza of Memorial Sloan Kettering explains how small cell lung cancer and non-small cell lung cancer are differentiated. February 2014.
Targeting the RAF Pathway in Lung Cancer
07 May 2014
Contributed by Lukas
Dr. Charles Rudin of Memorial Sloan Kettering talks about RAF and other genetic mutations that play a role in the growth of lung cancer. February 2014...
Is It Possible to Test Lung Tumors Without Doing a Biopsy?
06 May 2014
Contributed by Lukas
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute talks about exciting new developments which will allow oncologists to test patients' lung tumors w...
What Are PARP Inhibitors, and Might They Improve Outcomes in Small Cell Lung Cancer?
05 May 2014
Contributed by Lukas
Dr. Charles Rudin of Memorial Sloan Kettering on how PARP inhibitors may benefit patients with small cell lung cancer. February 2014.
New Insights into Small Cell Lung Cancer
04 May 2014
Contributed by Lukas
Dr. Cathy Pietanza of Memorial Sloan Kettering on the new avenues of research into the treatment of small cell lung cancer. February 2014.
In What Clinical Setting Should Immunotherapies Be Developed?
01 May 2014
Contributed by Lukas
Dr. Charles Rudin of Memorial Sloan Kettering discusses immune therapies that show promise in fighting lung cancer. February 2014.
Maintenance Therapy in Small Cell Lung Cancer
17 Apr 2014
Contributed by Lukas
Dr. Cathy Pietanza of Memorial Sloan Kettering on current and emerging treatments that are given to help keep small cell lung cancer from coming back ...
LDE225 and Small Cell Lung Cancer
17 Apr 2014
Contributed by Lukas
Dr. Cathy Pietanza of Memorial Sloan Kettering talks about a drug currently in clinical trials that may successfully treat small cell lung cancer. Feb...
Is There a Silver Bullet for Small Cell Lung Cancer?
17 Apr 2014
Contributed by Lukas
Dr. Cathy Pietanza of Memorial Sloan Kettering discusses potential areas of success in the treatment of small cell lung cancer. February 2014.
Advice for Newly Diagnosed Small Cell Lung Cancer Patients
17 Apr 2014
Contributed by Lukas
Dr. Cathy Pietanza of Memorial Sloan Kettering offers suggestions for newly diagnosed small cell lung cancer patients. February 2014.
PARP Inhibitors in Small Cell Lung Cancer
17 Apr 2014
Contributed by Lukas
Dr. Cathy Pietanza of Memorial Sloan Kettering talks about the role of PARP inhibitors in the treatment of small cell lung cancer. February 2014.
What's the Status and Potential Utility of Cabozantinib in Lung Cancer?
17 Apr 2014
Contributed by Lukas
Dr. Heather Wakelee of Stanford University Medical Center discusses whether or not cabozantinib - a drug already approved for thyroid cancer - can hel...
MK-3475 and its Efficacy in Lung Cancer
17 Apr 2014
Contributed by Lukas
Dr. Edward Garon discusses what researchers are learning about MK-3475, an immune therapy treatment currently in clinical trial. February 2014.
How Do the Different Immune Checkpoint Inhibitors in Lung Cancer Compare?
17 Apr 2014
Contributed by Lukas
Dr. Edward Garon warns that it is still too early to compare which immune therapies will be more effective in treating lung cancer.February 2014.
Do you see PARP inhibitors as a single drug therapy or more in a combination setting?
17 Apr 2014
Contributed by Lukas
Dr. Cathy Pietanza of Memorial Sloan Kettering discusses whether PARP treatments can be taken alone or if they must be taken with other drugs. Februar...
Late Stage Oropharynx Cancer, Chemotherapy - Options and Practice (video)
16 Apr 2014
Contributed by Lukas
Dr. Jared Weiss, University of North Carolina, discusses chemotherapy options and practice in late stage oropharynx cancer.
Late Stage Oropharynx Cancer, Chemotherapy - Options and Practice (audio)
16 Apr 2014
Contributed by Lukas
Dr. Jared Weiss, University of North Carolina, discusses chemotherapy options and practice in late stage oropharynx cancer.
ALK Positive Lung Cancer Forum 2014: Repeat Biopsies
04 Apr 2014
Contributed by Lukas
Why would an ALK lung cancer patient need a repeat biopsy? The doctors discuss the need for and frequency of repeat biopsies.
ALK Positive Lung Cancer Forum 2014: Next Generation ALK Inhibitors
04 Apr 2014
Contributed by Lukas
Several new treatments for ALK positive lung cancer patients are on the horizon. In this video, the doctors discuss them while patients in the audienc...
ALK Positive Lung Cancer Forum 2014: Disease Progression While on Xalkori
04 Apr 2014
Contributed by Lukas
New treatments for ALK rearrangements are on the horizon. In this video, the doctors discuss how they determine whether or not they change treatments ...
ALK Positive Lung Cancer Forum 2014: Scanning for Progression
04 Apr 2014
Contributed by Lukas
How often should ALK patients receive scans to determine if their disease has progressed in various parts of the body?
ALK Positive Lung Cancer Forum 2014: Risk of Flare After Stopping Targeted Therapy
04 Apr 2014
Contributed by Lukas
The doctors discuss how patients can navigate the tricky waters of stopping therapy while avoiding painful and sometimes life-threatening flare.
ALK Positive Lung Cancer Forum 2014: Can I Pass ALK Onto My Children
04 Apr 2014
Contributed by Lukas
ALK positive lung cancer typically shows up in people do not appear to be at high risk for the disease, so is this something that a lung cancer patien...
ALK Positive Lung Cancer Forum 2014: Testing for ALK
04 Apr 2014
Contributed by Lukas
Who should be tested for ALK? How is ALK tested and how reliable are the results? In this video, the doctors discuss several issues surrounding the is...
ALK Positive Lung Cancer Forum 2014: Xalkori
04 Apr 2014
Contributed by Lukas
Xalkori (crizotinib) was one of the fastest approved drugs in cancer treatment history because of its high efficacy levels in ALK positive lung c...
ALK Positive Lung Cancer Forum 2014: ALK Rearrangements in Lung Cancer
04 Apr 2014
Contributed by Lukas
The doctors discuss the history of ALK in lung cancer treatments and what the ALK rearragement means for patients.
Late Stage Oropharynx Cancer, Treatment and Side Effects (video)
30 Mar 2014
Contributed by Lukas
Dr. Geoffrey Geiger, University of Pennsylvania, outlines the course of radiotherapy treatment and side effects for head and neck cancer.
Late Stage Oropharynx Cancer, Treatment and Side Effects (audio)
30 Mar 2014
Contributed by Lukas
Dr. Geoffrey Geiger, University of Pennsylvania, outlines the course of radiotherapy treatment and side effects for head and neck cancer.
Late Stage Oropharynx Cancer, Planning for External Beam Radiotherapy (video)
30 Mar 2014
Contributed by Lukas
Dr. Geoffrey Geiger, University of Pennsylvania, discusses the process of planning radiotherapy for head and neck cancer.
Late Stage Oropharynx Cancer, Planning for External Beam Radiotherapy (audio)
30 Mar 2014
Contributed by Lukas
Dr. Geoffrey Geiger, University of Pennsylvania, discusses the process of planning radiotherapy for head and neck cancer.
Late Stage Oropharynx Cancer, Introduction and Management (video)
30 Mar 2014
Contributed by Lukas
Dr. Geoffrey Geiger, University of Pennsylvania, provides an introduction to head and neck cancer and the human papilloma virus.
Late Stage Oropharynx Cancer, Introduction and Management (audio)
30 Mar 2014
Contributed by Lukas
Dr. Geoffrey Geiger, University of Pennsylvania, provides an introduction to head and neck cancer and the human papilloma virus.
Squamous Lung Cancer Part 5, Q and A Session (video)
20 Dec 2013
Contributed by Lukas
Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.
Squamous Lung Cancer Part 5, Q and A Session (audio)
20 Dec 2013
Contributed by Lukas
Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.
Squamous Lung Cancer, Part 4: Immunotherapy (video)
10 Dec 2013
Contributed by Lukas
Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.
Squamous Lung Cancer, Part 4: Immunotherapy (audio)
10 Dec 2013
Contributed by Lukas
Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.
Squamous Lung Cancer, Part 3: Treatment (video)
08 Dec 2013
Contributed by Lukas
Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.
Squamous Lung Cancer, Part 3: Treatment (audio)
08 Dec 2013
Contributed by Lukas
Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.
Squamous Lung Cancer, Part 2: Genomic Testing (video)
06 Dec 2013
Contributed by Lukas
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.
Squamous Lung Cancer, Part 2: Genomic Testing (audio)
06 Dec 2013
Contributed by Lukas
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.
Squamous Lung Cancer, Part 1: Diagnosis, Presentation and Workup (video)
02 Dec 2013
Contributed by Lukas
Dr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.
Squamous Lung Cancer, Part 1: Diagnosis, Presentation and Workup (audio)
02 Dec 2013
Contributed by Lukas
Dr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.
Chemotherapy for Pancreatic Cancer, Part 6: Moving Forward in Advanced Pancreatic Cancer (audio)
28 Sep 2013
Contributed by Lukas
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews novel approaches, including nab-paclitaxel with gemcitabine, i...
Chemotherapy for Pancreatic Cancer, Part 6: Moving Forward in Advanced Pancreatic Cancer (video)
28 Sep 2013
Contributed by Lukas
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews novel approaches, including nab-paclitaxel with gemcitabine, i...
Chemotherapy for Pancreatic Cancer, Part 5: Chemotherapy for Metastatic Pancreatic Cancer (video)
28 Sep 2013
Contributed by Lukas
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, discusses the history of and recent developments in chemotherapy for m...
Chemotherapy for Pancreatic Cancer, Part 5: Chemotherapy for Metastatic Pancreatic Cancer (audio)
28 Sep 2013
Contributed by Lukas
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, discusses the history of and recent developments in chemotherapy for m...
Chemotherapy for Pancreatic Cancer, Part 4: Post-Operative (Adjuvant) Treatment for Pancreatic Cancer (video)
21 Sep 2013
Contributed by Lukas
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for post-operative (adjuvant) therap...
Chemotherapy for Pancreatic Cancer, Part 4: Post-Operative (Adjuvant) Treatment for Pancreatic Cancer (audio)
21 Sep 2013
Contributed by Lukas
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for post-operative (adjuvant) therap...
Chemotherapy for Pancreatic Cancer, Part 3: Pre-Operative Treatment for Pancreatic Cancer (video)
19 Sep 2013
Contributed by Lukas
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for pre-operative (neoadjuvant) ther...
Chemotherapy for Pancreatic Cancer, Part 3: Pre-Operative Treatment for Pancreatic Cancer (audio)
19 Sep 2013
Contributed by Lukas
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancre...
Chemotherapy for Pancreatic Cancer, Part 2: Resectable vs. Unresectable Pancreatic Cancer (video)
09 Sep 2013
Contributed by Lukas
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancre...
Chemotherapy for Pancreatic Cancer, Part 2: Resectable vs. Unresectable Pancreatic Cancer (audio)
09 Sep 2013
Contributed by Lukas
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancre...
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (video)
04 Sep 2013
Contributed by Lukas
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in ...
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)
04 Sep 2013
Contributed by Lukas
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in ...
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (video)
31 Aug 2013
Contributed by Lukas
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor gane...
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (audio)
31 Aug 2013
Contributed by Lukas
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor gane...
ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (video)
26 Aug 2013
Contributed by Lukas
Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedan...
ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (audio)
26 Aug 2013
Contributed by Lukas
Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedan...
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (video)
26 Aug 2013
Contributed by Lukas
Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation AL...
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)
26 Aug 2013
Contributed by Lukas
Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation AL...